Filtered By:
Condition: Thrombosis
Therapy: Thrombolytic Therapy

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 1360 results found since Jan 2013.

The Totaled Health Risks in Vascular Events (THRIVE) Score Predicts Ischemic Stroke Outcomes Independent of Thrombolytic Therapy in the NINDS tPA Trial
Conclusions: The THRIVE score provides accurate prediction of long-term neurologic outcomes in patients with acute ischemic stroke regardless of treatment modality. Both the THRIVE score and tPA administration predict outcome, but the THRIVE score does not influence the impact of tPA on outcome, and tPA administration does not influence the impact of THRIVE score on outcome.
Source: Journal of Stroke and Cerebrovascular Diseases - November 5, 2012 Category: Neurology Authors: Hooman Kamel, Nihar Patel, Vivek A. Rao, Sean P. Cullen, Bonnie S. Faigeles, Wade S. Smith, Alexander C. Flint Tags: Original Articles Source Type: research

The CHA(2)DS(2)-VASc Score Reflects Clinical Outcomes in Nonvalvular Atrial Fibrillation Patients with an Initial Cardioembolic Stroke
Conclusions: The severity of NVAF-induced initial cardioembolic stroke increased with higher CHA(2)DS(2)-VASc scores, and the outcomes were poor. The present study suggests that the CHA(2)DS(2)-VASc score may be useful not only for the evaluation of stroke risk but also for the prediction of clinical outcomes after stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - March 25, 2013 Category: Neurology Authors: Ichiro Deguchi, Takeshi Hayashi, Yasuko Ohe, Yuji Kato, Harumitsu Nagoya, Takuya Fukuoka, Hajime Maruyama, Yohsuke Horiuchi, Norio Tanahashi Tags: Original Articles Source Type: research

Perception Of Stroke Symptoms And Utilization Of Emergency Medical Systems In Argentina (P7.132)
CONCLUSIONS:These results suggest a low level of stroke symptoms awareness in our country even in a population of middle/high socioeconomic level. The role and procedures of EMS in Argentina should be revised as early arrival and treatment appear to be associated with no utilization of them.Study Supported by:Disclosure: Dr. Hawkes has nothing to disclose. Dr. Calandri has nothing to disclose. Dr. Farez has received personal compensation for activities with Merck Serono. Dr. Farez has received research support from Novartis. Dr. Arena has nothing to disclose. Dr. Pujol Lereis has nothing to disclose. Dr. Ameriso has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Hawkes, M., Calandri, I., Farez, M., Arena, J., Pujol Lereis, V., Ameriso, S. Tags: Cerebrovascular Disease and Interventional Neurology: Barriers and Opportunities in Acute Stroke Treatment Source Type: research

Initial Body Temperature in Ischemic Stroke: Nonpotentiation of Tissue-Type Plasminogen Activator Benefit and Inverse Association With Severity Clinical Sciences
Conclusions— In patients with hyperacute stroke, higher presenting temperatures are associated with less severe neurological deficits and reduced final infarct volumes. Presenting temperature does not modify the benefit of tPA on 3-month favorable outcome.
Source: Stroke - December 22, 2014 Category: Neurology Authors: Kim, S. H., Saver, J. L. Tags: Thrombolysis Clinical Sciences Source Type: research

Balancing access and quality in comprehensive stroke care
The establishment of stroke units and stroke centers has transformed the inpatient care of cerebrovascular disease and resulted in improved outcomes for patients hospitalized with stroke. Studies show that organized care as part of a stroke unit results in reduced mortality and disability after stroke,1 and that patients hospitalized at primary stroke centers have lower mortality and are more likely to receive thrombolytic therapy.2
Source: Neurology - March 23, 2015 Category: Neurology Authors: Kelly, A. G., Attia, J. Tags: All Health Services Research, Other cerebrovascular disease/ Stroke, All Cerebrovascular disease/Stroke, All epidemiology EDITORIALS Source Type: research

Fingolimod Reduces Hemorrhagic Transformation Associated With Delayed Tissue Plasminogen Activator Treatment in a Mouse Thromboembolic Model Basic Sciences
Conclusion— This study confirms the protective efficacy of fingolimod as a treatment against ischemic stroke in another rodent model of stroke (thromboembolic occlusion), and suggests that fingolimod could potentially be used in combination with tPA to reduce the risk of brain hemorrhage.
Source: Stroke - January 18, 2013 Category: Neurology Authors: Campos, F., Qin, T., Castillo, J., Seo, J. H., Arai, K., Lo, E. H., Waeber, C. Tags: Acute Cerebral Infarction, Embolic stroke, Emergency treatment of Stroke, Thrombolysis, Other Stroke Treatment - Medical Basic Sciences Source Type: research

Tissue Plasminogen Activator Thrombolytic Therapy for Acute Ischemic Stroke in 4 Hospital Groups in Japan
In October 2005 in Japan, the recombinant tissue plasminogen activator (tPA) alteplase was approved for patients with acute ischemic stroke within 3 hours of onset at a dose of 0.6 mg/kg. The present study was undertaken to assess the safety and efficacy of alteplase in Japan. Between October 2005 and December 2009, a total of 114 consecutive patients admitted to 4 hospitals received intravenous tPA within 3 hours of stroke onset. Clinical backgrounds and outcomes were investigated. The patients were divided into 2 chronological groups: an early group, comprising 45 patients treated between October 2005 and December 2007,...
Source: Journal of Stroke and Cerebrovascular Diseases - October 4, 2011 Category: Neurology Authors: Syoichiro Kono, Kentaro Deguchi, Nobutoshi Morimoto, Tomoko Kurata, Shoko Deguchi, Tohru Yamashita, Yoshio Ikeda, Tohru Matsuura, Hisashi Narai, Nobuhiko Omori, Yasuhiro Manabe, Taijyun Yunoki, Yoshiki Takao, Sanami Kawata, Kenichi Kashihara, Koji Abe Tags: Original Articles Source Type: research

The Effect of Ginkgo biloba on Functional Outcome of Patients with Acute Ischemic Stroke: A Double-blind, Placebo-controlled, Randomized Clinical Trial
Background: Acute ischemic stroke is a major cerebrovascular disease with potential morbidity and mortality. Despite the availability of thrombolytic therapy in some centers, risk factor modification and rehabilitation therapy are the mainstays of stroke management. There is supporting evidence that Ginkgo biloba may afford neuroprotection and improve the outcomes of patients with acute ischemic stroke.Methods: In a double-blind, placebo-controlled, randomized controlled trial, we assessed the efficacy of G biloba on functional outcome in patients with acute stroke. The National Institutes of Heath Stroke Scale (NIHSS) wa...
Source: Journal of Stroke and Cerebrovascular Diseases - July 22, 2013 Category: Neurology Authors: Darioush Savadi Oskouei, Reza Rikhtegar, Mazyar Hashemilar, Homayoun Sadeghi-Bazargani, Mohsen Sharifi-Bonab, Elyar Sadeghi-Hokmabadi, Sina Zarrintan, Ehsan Sharifipour Tags: Original Articles Source Type: research

Should minor stroke patients be thrombolyzed? A focused review and future directions
Stroke is a leading cause of morbidity and mortality worldwide. Up to 80% of ischemic stroke patients may initially present with minor symptoms. Minor stroke and transient ischemic attack patients are typically treated conservatively with antiplatelet agents and general vascular prevention strategies. Yet a high proportion develop recurrent stroke or progression of stroke and up to one in four of these patients are disabled or dead at follow‐up. Minor or rapidly improving symptoms are the top reasons for withholding thrombolytic therapy to time‐eligible stroke patients as they are believed to be ‘too good to treat’...
Source: International Journal of Stroke - December 25, 2014 Category: Neurology Authors: Amy Y. X. Yu, Michael D. Hill, Shelagh B. Coutts Tags: Review (invited) Source Type: research

Embolic stroke with spontaneous recanalization (P3.085)
Conclusions This study infers that thrombolysis remarkably improves clinical outcome in patients with embolic stroke who do not have visible arterial occlusion at presentation. A prospective study to validate these results is being planned.Disclosure: Dr. Lahoti has nothing to disclose. Dr. Gokhale has nothing to disclose. Dr. Caplan has received personal compensation in an editorial capacity for JAMA Neurology. Dr. Michel has received personal compensation for activities with Servier, Sanofi-Aventis Pharmaceuticals, and Boehringer Ingelheim Pharmaceuticals, as a speaker, steering committee member, and/or advisory board me...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Lahoti, S., Gokhale, S., Caplan, L., Michel, P., Samson, Y., Rosso, C., Limaye, K., Hinduja, A., Singhal, A., Ali, S., Kryscio, R., Dedhia, N., Hastak, S., Liebeskind, D., Pettigrew, L. Tags: Cerebrovascular Disease and Interventional Neurology: Hemorrhagic and Ischemic Stroke Source Type: research

Knowledge of Acute Stroke Management Among Healthcare Professionals: Development and Validation of Acute Stroke Management Questionnaire (ASMaQ)
Around 15.0% of all strokes occurred in hospitalised patients and studies showed significant delay in the stroke recognition and lack of awareness on thrombolytic therapy for acute ischaemic stroke (AIS) which lead to higher mortality for in-hospital stroke. We aimed to develop and validate a new instrument known as acute stroke management questionnaire (ASMaQ) to evaluate the awareness of healthcare professionals in managing acute ischaemic stroke cases.
Source: Journal of Stroke and Cerebrovascular Diseases - November 4, 2020 Category: Neurology Authors: Chun yang Sim, Wan Asyraf Wan Zaidi, Shamsul Azhar Shah, Wan Nur Nafisah Wan Yahya, Hui jan Tan Source Type: research

Prediction of Thrombolytic Therapy after Stroke-Bypass Transportation: The Maria Prehospital Stroke Scale Score
There is no prehospital stratification tool specifically for predicting thrombolytic therapy after transportation. We developed a new prehospital scale named the Maria Prehospital Stroke Scale (MPSS) by modifying the Cincinnati Prehospital Stroke Scale. Our objective is to evaluate its utility in a citywide bypass transportation protocol for intravenous (IV) tissue plasminogen activator (tPA). In the MPSS, facial droop, arm drift, and speech disturbance are tested by emergency medical technicians (EMTs). Facial droop is graded as normal (0) or abnormal (1), and the other 2 items are graded in 3 levels as normal (0), not se...
Source: Journal of Stroke and Cerebrovascular Diseases - March 13, 2013 Category: Neurology Authors: Yasuhiro Hasegawa, Naoshi Sasaki, Koji Yamada, Hajime Ono, Junichiro Kumai, Kotaro Tsumura, Kazunari Suzuki, Hiroyuki Nozaki, Hitoshi Nakayama, Ichiro Takumi, Hirofumi Nikaido, Tuyoshi Katabami, Toshihiro Ueda, Shinichi Suzuki, Ryosei Iwai, Hiroshi Takaha Tags: Original Articles Source Type: research

Validity of a computerised five-level emergency triage system for patients with acute ischaemic stroke
Conclusion Acuity measured by the computerised TTAS demonstrated good validity in facilitating acute care of stroke patients with special regard to thrombolytic therapy.
Source: Emergency Medicine Journal - May 13, 2013 Category: Emergency Medicine Authors: Sung, S.-F., Huang, Y.-C., Ong, C.-T., Chen, W. Tags: Drugs: cardiovascular system, Stroke, Radiology, Adult intensive care, Clinical diagnostic tests Original article Source Type: research

Exclusion Criteria for Intravenous Thrombolysis in Stroke Mimics: An Observational Study
Conclusions: SM patients frequently had exclusion criteria for systemic thrombolysis, the most frequent being presenting beyond the established thrombolytic window.
Source: Journal of Stroke and Cerebrovascular Diseases - December 17, 2012 Category: Neurology Authors: Alejandro M. Brunser, Sergio Illanes, Pablo M. Lavados, Paula Muñoz, Daniel Cárcamo, Arnold Hoppe, Verónica V. Olavarria, Iris Delgado, Violeta Díaz Tags: Original Articles Source Type: research

Influence of racial differences on outcomes after thrombolytic therapy in acute ischemic stroke
ConclusionsThese results do not suggest a differential response to tissue plasminogen activator based on race ethnicity. Among Asians, data were particularly sparse, and results should be interpreted with caution.
Source: International Journal of Stroke - October 22, 2013 Category: Neurology Authors: Nishant K. Mishra, Pitchaiah Mandava, Christopher Chen, James Grotta, Kennedy R. Lees, Thomas A. Kent, Tags: Research Source Type: research